株探米国株
英語
エドガーで原本を確認する

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of August 2024.

 

Commission File Number 001-40772

 

Cellebrite DI Ltd.

(Translation of registrant’s name into English)

 

94 Shlomo Shmelzer Road

Petah Tikva 4970602, Israel

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒      Form 40-F ☐

 

 

 

 


 

EXPLANATORY NOTE

 

This Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) filed by Cellebrite DI Ltd. (the “Company”) consists of the Company’s: (i) consolidated financial statements for the six months ended June 30, 2024, which are attached hereto as Exhibit 99.1 and are incorporated by reference herein; and (ii) operating and financial review and prospects (unaudited) for the six months ended June 30, 2024, which are attached hereto as Exhibit 99.2 and are incorporated by reference herein.

 

This Form 6-K, including its exhibits, is incorporated by reference into the Company’s registration statements on Form F-3 (File No. 333-259826) filed with the U.S. Securities and Exchange Commission (the “SEC”) on September 13, 2022 and Forms S-8 (File Nos. 333-260878 and 333-278130) filed with the SEC on November 8, 2021 and March 21, 2024, respectively.

 

1


 

EXHIBIT INDEX

 

Exhibit No.   Exhibit
99.1   Consolidated financial statements of Cellebrite DI Ltd. and its subsidiaries for the six-months ended June 30, 2024.
99.2   Operating and Financial Review and Prospects for the six months ended June 30, 2024.
101.INS   Inline XBRL Instance Document.
101.SCH   Inline XBRL Taxonomy Extension Schema Document.
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Cellebrite DI Ltd.
     
August 15, 2024 By: /s/ Dana Gerner
    Dana Gerner
    Chief Financial Officer

 

3

 

2024-06-30

Exhibit 99.1

 

CONSOLIDATED FINANCIAL STATEMENTS

 

CELLEBRITE DI LTD. AND ITS SUBSIDIARIES

INTERIM CONSOLIDATED FINANCIAL STATEMENT

AS OF JUNE 30, 2024

UNAUDITED

INDEX

 

  Page
Interim Consolidated Balance Sheets (Unaudited) F-2
Interim Consolidated Statements of Comprehensive Loss (Unaudited) F-3
Interim Consolidated Statements of Changes in Shareholders’ (deficiency) Equity (Unaudited) F-5
Interim Consolidated Statements of Cash Flows (Unaudited) F-6
Notes to Interim Consolidated Financial Statements (Unaudited) F-7

 

F-1


 

Cellebrite DI Ltd. and its Subsidiaries

 

INTERIM CONSOLIDATED BALANCE SHEETS
(U.S Dollars in thousands, except share and per share data)

 

        June 30,     December 31,  
      2024     2023  
    Note   Unaudited        
Assets                
Current assets                
Cash and cash equivalents       $ 106,956     $ 189,517  
Short-term deposits         126,723       74,713  
Marketable securities   3     71,630       38,693  
Trade receivables (net of allowance for credit losses of $2,019 and $1,583 as of June 30, 2024 and December 31, 2023, respectively)         70,699       77,269  
Prepaid expenses and other current assets         24,443       26,400  
Contract acquisition costs         5,516       5,550  
Inventories         8,784       9,940  
Total current assets         414,751       422,082  
                     
Non-current assets                    
Other non-current assets         8,224       7,341  
Marketable securities   3     60,652       28,859  
Deferred tax assets, net         8,806       7,024  
Property and equipment, net         15,806       15,896  
Intangible assets, net         9,807       10,594  
Goodwill         26,829       26,829  
Operating lease right-of-use assets, net   5     11,708       14,260  
Total non-current assets         141,832       110,803  
                     
Total assets       $ 556,583     $ 532,885  
                     
Liabilities and Shareholders’ (deficiency) equity                    
                     
Current Liabilities                    
Trade payables       $ 6,510     $ 8,282  
Other accounts payable and accrued expenses         42,259       44,845  
Deferred revenues         183,938       195,725  
Operating lease liabilities   5     4,521       4,972  
Total current liabilities         237,228       253,824  
                     
Long-term liabilities                    
Other long-term liabilities         6,492       5,515  
Deferred revenues         42,369       47,098  
Restricted Sponsor Shares liability   9     75,230       47,247  
Price Adjustment Shares liability   9     134,758       81,715  
Warrant liability   9     93,510       54,117  
Operating lease liabilities   5     7,155       9,157  
Total long-term liabilities         359,514       244,849  
                     
Total liabilities       $ 596,742     $ 498,673  
                     
Shareholders’ (deficiency) equity   7                
Share capital, NIS 0.00001 par value; 3,454,112,863 shares authorized, 207,675,806 and 203,272,704 shares issued and 207,634,030 and 203,230,928 shares outstanding as of June 30, 2024 (unaudited) and December 31, 2023, respectively         *)       *)  
Additional paid-in capital         (64,284 )     (84,896 )
Treasury share, NIS 0.00001 par value; 41,776 ordinary shares         (85 )     (85 )
Accumulated other comprehensive income         1,250       1,050  
Retained earnings         22,960       118,143  
Total shareholders’ (deficiency) equity         (40,159 )     34,212  
                     
Total liabilities and shareholders’ (deficiency) equity       $ 556,583     $ 532,885  

 

*) Less than 1 USD

 

F-2


 

Cellebrite DI Ltd. and its Subsidiaries
 
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)
(U.S Dollars in thousands, except share and per share data)

 

        For the six months ended  
        June 30,  
      2024     2023  
    Note   Unaudited     Unaudited  
                 
Revenue:   10            
Subscription services       $ 127,841     $ 97,879  
Term-license         36,749       30,609  
Total subscription         164,590       128,488  
Other non-recurring         7,054       4,890  
Professional services         13,652       14,540  
Total revenue         185,296       147,918  
                     
Cost of revenue:                    
Subscription services         12,197       9,438  
Term-license        
      2  
Total subscription         12,197       9,440  
Other non-recurring         7,920       5,907  
Professional services         9,408       10,090  
Total cost of revenue         29,525       25,437  
                     
Gross profit       $ 155,771     $ 122,481  
                     
Operating expenses:                    
Research and development         46,890       42,184  
Sales and marketing         64,379       54,346  
General and administrative         22,768       21,192  
Total operating expenses         134,037       117,722  
                     
Operating income       $ 21,734     $ 4,759  
Financial expense, net   11     (113,078 )     (74,826 )
Loss before tax         (91,344 )     (70,067 )
Tax expense         3,839       2,886  
Net loss       $ (95,183 )   $ (72,953 )
                     
Loss per share                    
Basic       $ (0.48 )   $ (0.37 )
Diluted       $ (0.48 )   $ (0.37 )
                     
Weighted average shares outstanding                    
Basic         197,840,662       187,239,136  
Diluted         197,840,662       187,239,136  

 

F-3


 

Cellebrite DI Ltd. and its Subsidiaries
 
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)
(U.S Dollars in thousands, except share and per share data)

 

        For the six months ended  
        June 30,  
      2024     2023  
    Note   Unaudited     Unaudited  
                 
Net loss     $ (95,183 )   $ (72,953 )
                     
Change in foreign currency translation adjustment         1,370       (966 )
                     
Change in unrealized (losses) gains on marketable securities:                    
Unrealized (losses) gains arising during the period         (320 )     126  
                     
Net change (net of tax effect of $98 and $(48))         (320 )     126  
                     
Change in unrealized (losses) gains on cash flow hedges:   4                
Unrealized losses arising during the period         (652 )     (671 )
Less -reclassification adjustment for net (losses) gains realized and included in net income         (198 )     697  
                     
Net change (net of tax effect of $116  and (4))         (850 )     26  
                     
Total other comprehensive income (loss)         200       (814 )
                     
Comprehensive loss       $ (94,983 )   $ (73,767 )

 

F-4


 

Cellebrite DI Ltd. and its Subsidiaries
 
INTERIM CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS’ (DEFICIENCY) EQUITY (Unaudited)
(U.S Dollars in thousands, except share and per share data)

 

    Six months ended June 30, 2024  
    Ordinary Shares Amount     Share Capital     Additional paid in capital     Treasury Share     Retained earnings     Accumulated other comprehensive income     Total  
Balance as of December 31, 2023     203,230,928       * )   $ (84,896 )   $    (85 )   $ 118,143     $    1,050     $ 34,212  
Exercise of share option and vested RSUs and ESPP     4,403,102       * )     8,361      
     
     
      8,361  
Share-based compensation expense and ESPP benefit                 12,251            
     
      12,251  
Other comprehensive loss                
           
      200       200  
Net loss                
            (95,183 )    
      (95,183 )
Balance as of June 30, 2024     207,634,030       * )   $ (64,284 )   $ (85 )   $ 22,960     $ 1,250     $ (40,159 )

 

    Six months ended June 30, 2023  
    Ordinary Shares Amount     Share Capital     Additional paid in capital     Treasury Share     Retained earnings    

Accumulated other comprehensive

 loss

    Total  
Balance as of December 31, 2022     193,014,155       * )   $ (125,624 )   $    (85 )   $ 199,243     $         331     $ 73,865  
Exercise of share option, vested RSUs and ESPP     4,353,685       * )     8,401      
     
     
      8,401  
Share-based compensation expense and ESPP benefit                 9,057            
     
      9,057  
Other comprehensive loss                
           
      (814 )     (814 )
Net loss                
            (72,953 )    
      (72,953 )
Balance as of June 30, 2023     197,367,840       * )   $ (108,166 )   $ (85 )   $ 126,290     $ (483 )   $ 17,556  

 

*) Less than 1 USD

 

F-5


 

Cellebrite DI Ltd. and its Subsidiaries
 
INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited)
(U.S Dollars in thousands, except share and per share data)

 

    For the six months ended  
    June 30,  
    2024     2023  
    Unaudited     Unaudited  
             
Cash flow from operating activities:            
             
Net loss   $ (95,183 )   $ (72,953 )
Adjustments to reconcile net income to net cash provided by operating activities:                
Share based compensation     12,251       9,057  
Amortization of premium, discount and accrued interest on marketable securities     (1,302 )     (461 )
Depreciation and amortization     5,256       5,016  
Interest income from short term deposits     (5,470 )     (2,397 )
Deferred income taxes     (1,568 )     462  
Remeasurement of warrant liability     39,393       22,263  
Remeasurement of Restricted Sponsor Shares     27,983       20,093  
Remeasurement of Price Adjustment Shares liabilities     53,043       36,597  
Decrease in trade receivables     6,021       18,117  
(Decrease) increase in deferred revenue     (15,055 )     10,555  
Increase in other non-current assets     (883 )     (1,062 )
Decrease (increase) in prepaid expenses and other current assets     2,752       (5,624 )
Changes in operating lease assets     2,641       2,700  
Changes in operating lease liability     (2,542 )     (2,962 )
Decrease (increase) in inventories     1,151       (642 )
(Decrease) increase in trade payables     (1,591 )     381  
Decrease in other accounts payable and accrued expenses     (3,320 )     (9,741 )
Increase (decrease) in other long-term liabilities     977       (347 )
Net cash provided by operating activities     24,554       29,052  
                 
Cash flows from investing activities:                
                 
Purchases of property and equipment     (3,568 )     (1,889 )
Purchase of Intangible assets     (904 )    
 
Investment in marketable securities     (99,282 )     (27,005 )
Proceeds from maturity of marketable securities     35,436       29,507  
Investment in short-term deposits     (122,000 )     (54,000 )
Redemption of short-term deposits     75,459       38,581  
Net cash used in investing activities     (114,859 )     (14,806 )
                 
Cash flows from financing activities:                
                 
Exercise of options to shares     6,887       7,185  
Proceeds from Employee Share Purchase Plan     1,506       1,234  
Net cash provided by financing activities     8,393       8,419  
                 
Net (decrease) increase in cash and cash equivalents     (81,912 )     22,665  
Net effect of Currency Translation on cash and cash equivalents     (649 )     192  
Cash and cash equivalents at beginning of period     189,517       87,645  
Cash and cash equivalents at end of period   $ 106,956     $ 110,502  
                 
Supplemental cash flow information:                
Income taxes paid   $ 2,557     $ 8,527  
Non-cash activities                
Operating lease liabilities arising from obtaining right of use assets
    215       1,258  

 

F-6


 

  Cellebrite DI Ltd. and its Subsidiaries
   
Notes to Interim Consolidated Financial Statements
U.S. dollars (in thousands, except share and per share data)

 

Note 1. General

 

Cellebrite DI Ltd. (the “Company”), an Israeli company, was incorporated on April 13, 1999 as a private company, and began its operations in July 1999. The Company and its wholly owned subsidiaries delivering a digital investigative (“DI”) suite of solutions comprising software and services for legally sanctioned investigations. The Company’s DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations The Company’s primary shareholder is SUNCORPORATION, a public company traded in the Japanese market (see also Note 12).

 

On April 8, 2021, the Company entered into a Business Combination Agreement and Plan of Merger (the “Merger Agreement”) with TWC Tech Holdings II Corp. (“TWC”), a public listed company in Nasdaq and Cupcake Merger Sub, Inc., a new wholly-owned subsidiary of Cellebrite (the “Merger Sub”) in the USA. TWC is a Special Purpose Acquisition Company (“SPAC”). On August 30, 2021, the Merger was consummated. Upon the terms and subject to the conditions of the Merger Agreement, at the Effective Time, Merger Sub merged with and into TWC, the separate corporate existence of Merger Sub ceased and TWC became the surviving corporation and a wholly-owned subsidiary of the Company (the “Merger”). TWC became a wholly-owned subsidiary of the Company and the security holders of TWC became security holders of the Company. In December 2023, TWC was dissolved.

 

Note 2. Summary of Significant Accounting Policies

 

A. Unaudited interim consolidated financial statements:

 

The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information. In the opinion of management, the unaudited interim consolidated financial statements include all adjustments necessary for a fair presentation.

 

The balance sheet as of December 31, 2023 has been derived from the audited consolidated financial statements of the Company at that date but does not include all information and footnotes required by U.S. GAAP for complete financial statements.

 

The accompanying unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2023. Results for the six months ended June 30, 2024 are not necessarily indicative of results that may be expected for the year ending December 31, 2024.

 

The significant accounting policies applied in the annual consolidated financial statements of the Company as of December 31, 2023, have been applied consistently in these unaudited interim condensed consolidated financial statements.

 

Trade Receivable and Allowances

 

Trade receivables are recorded net of credit losses allowance for any potential uncollectible amounts.

 

The Company makes estimates of expected credit and collectability trends for the allowance for credit losses based upon its assessment of various factors, including historical collectability experience, the age of the trade receivable balances, credit quality of its customers, current economic conditions, reasonable and supportable forecasts of future economic conditions, and other factors that may affect its ability to collect from customers.

 

F-7


 

  Cellebrite DI Ltd. and its Subsidiaries
   
Notes to Interim Consolidated Financial Statements
U.S. dollars (in thousands, except share and per share data)

 

As of June 30, 2024 and December 31, 2023, the allowances for credit losses of trade receivable were $2,019 and $1,583 respectively.

 

The Company writes off receivables when they are deemed uncollectible, having exhausted all collection efforts. Actual collection experience may not meet expectations and may result in increased bad debt expense.

 

B. Use of estimates

 

The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods and accompanying notes. Actual results could differ from those estimates.

 

Significant items subject to such estimates and assumptions include, but are not limited to, the allocation of transaction price among various performance obligation, the fair value of acquired intangible assets and goodwill in a business combination, share-based compensation, unrecognized tax benefits, marketable securities, fair value measurement of restricted sponsor shares liability, price adjustment shares liability and warrant liabilities.

 

C. Fair value measurements

 

The Company accounts for fair value in accordance with ASC 820, “Fair Value Measurements and Disclosures”. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The Company uses a three-tier hierarchy, which prioritizes the inputs used in measuring fair value as follows:

 

Level 1: Quoted prices in active markets for identical assets or liabilities.

 

Level 2: Inputs other than Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.

 

Level 3: Unobservable inputs for the asset or liability used to measure fair value that are supported by little or no market activity and that re significant to the fair value of the asset or liability at measurement date.

 

The carrying value of trade receivable and payables and the Company’s cash and cash equivalents and short-term deposits, approximates fair value due to the short time to expected payment or receipt of cash.

 

F-8


 

  Cellebrite DI Ltd. and its Subsidiaries
   
Notes to Interim Consolidated Financial Statements
U.S. dollars (in thousands, except share and per share data)

 

D. Revenue recognition

 

The Company’s revenues are comprised of four main categories: (a) Subscription Services, including support services (updates, upgrades and technical support) on term-based licenses; (b) Term Licenses; (c) other non-recurring; and (d) professional services.

 

The Company recognizes revenue pursuant to the five-step framework contained in ASC 606, Revenue from Contracts with Customers: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations

 

The Company sells its products to its customers either directly or indirectly through distribution channels all of whom are considered end users.

 

In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services are delivered. The amount of revenue recognized reflects the consideration that the Company expects to receive in exchange for these goods or services.

 

The Company determines that it has a contract with a customer when each party’s rights regarding the products or services to be transferred can be identified, the payment terms for the services can be identified, the Company has determined the customer has the ability and intent to pay, and the contract has commercial substance. At contract inception, the Company evaluates whether two or more contracts should be combined and accounted for as a single contract and whether the combined or single contract includes more than one performance obligation.

 

Performance obligations promised in a contract are identified based on the products and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the products or services either on their own or together with other resources that are readily available from third parties or from the Company, and are distinct in the context of the contract, whereby the transfer of the products and services is separately identifiable from other promises in the contract.

 

The Company’s software licenses either provide its customers the right to use its software for a fixed term, or a perpetual right to use its software, in most cases between a one-year and three-year time frame. The Company concluded that the software license is distinct as the customer can benefit from the software on its own.

 

Subscription revenue is derived from maintenance and support under renewable subscription, fee-based contracts that include unspecified software updates and upgrades released when and if available as well as software support. Customers with active subscriptions are also entitled to our technical customers’ support. Performance obligations related to software maintenance services generally have a consistent continuous pattern of transfer to a customer during the contract period.

 

Other non-recurring revenue derived mostly from hardware sold mainly in conjunction with new software license, perpetual license and usage-based fees.

 

Professional services revenues primarily consist of: (i) certified training classes by Cellebrite Academy; (ii) our advanced services; (iii) implementation of our products in connection with our software licenses and (iv) on premise contracted customer success and technical support. Each of these performance obligations provide benefit to the customer on a standalone basis and are distinct in the context of the contract.

 

F-9


 

  Cellebrite DI Ltd. and its Subsidiaries
   
Notes to Interim Consolidated Financial Statements
U.S. dollars (in thousands, except share and per share data)

 

The transaction price is determined based on the consideration to which the Company expects to be entitled in exchange for transferring products or delivery of services to the customer. Payment terms generally are 30 days. The Company applied the practical expedient in ASC 606 and did not evaluate payment terms of one year or less for the existence of a significant financing component. Revenue is recognized net of any taxes collected from customers which are subsequently remitted to governmental entities (e.g., sales tax and other indirect taxes). The Company does not offer right of return to its contracts.

 

If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. For contracts that contain multiple performance obligations, the Company allocates the transaction price to each performance obligation based on the relative standalone selling price (“SSP”) for each performance obligation. The Company uses judgment in determining the SSP for its products and services. The Company typically assesses the SSP for its products and services on a periodic basis or when facts and circumstances change. To determine SSP, the Company maximizes the use of observable standalone sales and observable data, where available. In instances where performance obligations do not have observable standalone sales, the Company utilizes available information that may include the entity specific factors such as assessment of historical data of bundled sales of software licenses with other promised goods and services, and pricing strategies to estimate the price the Company would charge if the products and services were sold separately.

 

The Company satisfies performance obligations either over time or at a point in time depending on the nature of the underlying promise. Revenue is recognized at the time the related performance obligation is satisfied by transferring a promised good or service to a customer. Revenues related to the license for proprietary software are recognized when the control over the license is provided to the customer and the license term begins. Revenue related to software update and upgrades are recognized ratably over the service period. Revenues related to other professional services are recognized as services are performed.

 

E. Recently issued accounting pronouncements

 

Recently issued accounting pronouncements not yet adopted:

 

In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses on an interim and annual basis. All disclosure requirements of ASU 2023-07 are required for entities with a single reportable segment. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods for the fiscal years beginning after December 15, 2024, and should be applied on a retrospective basis to all periods presented. Early adoption is permitted. The Company is currently evaluating the effect of adopting the ASU on its disclosures.

 

In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures. The ASU requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, the ASU requires certain disclosures of state versus federal income tax expense and taxes paid. The amendments in this ASU are required to be adopted for fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments should be applied on a prospective basis. The Company is currently evaluating the effect of adopting the ASU on its disclosures.

 

F-10


 

  Cellebrite DI Ltd. and its Subsidiaries
   
Notes to Interim Consolidated Financial Statements
U.S. dollars (in thousands, except share and per share data)

 

F. Concentrations of credit risk

 

Financial instruments that potentially expose the Company and its subsidiaries to concentrations of credit risk consist principally of cash and cash equivalents, short-term investments, trade receivables and other receivables.

 

The majority of the Company’s cash and cash equivalents are invested in deposits mainly in dollars with major international banks. Generally, these cash and cash equivalents and short-term investment may be redeemed upon demand. Management believes that the financial institutions that hold the Company’s and its subsidiaries’ cash and cash equivalents are institutions with high credit standing, and accordingly, minimal credit risk exists with respect to these assets.

 

The Company’s trade receivables are geographically diversified and derived from sales to customers all over the world. The Company mitigates its credit risks by performing an ongoing credit evaluations of its customers’ financial conditions. The Company and its subsidiaries generally do not require collateral; however, in certain circumstances, the Company and its subsidiaries may require letters of credit, additional guarantees or advance payments.

 

The Company’s marketable securities consist of investments in government, corporate and government sponsored enterprises debentures. The Company’s investment policy, approved by the Board of Directors, limits the amount that the Company may invest in any one type of investment, or issuer, thereby reducing credit risk concentrations.

 

The Company enters into foreign currency forward and option contracts intended to protect cash flows resulting from scheduled payments such as payroll and rent related expenses against the volatility in value of forecasted non-dollar currency. The derivative instruments hedge a portion of the Company's non-dollar currency exposure.

 

F-11


 

  Cellebrite DI Ltd. and its Subsidiaries
   
Notes to Interim Consolidated Financial Statements
U.S. dollars (in thousands, except share and per share data)

 

Note 3. Marketable securities

 

Marketable securities consisted of the following:

 

    As of June 30, 2024  
    Amortized cost     Gross unrealized gains     Gross unrealized losses     Fair value  
    (Unaudited)  
Corporate bond     48,648      
      (209 )     48,439  
Agency bond     58,714       2       (161 )     58,555  
Treasury bills     10,029      
      (1 )     10,028  
US Government     15,303      
      (43 )     15,260  
Total     132,694       2       (414 )     132,282  

 

    As of December 31, 2023  
    Amortized cost     Gross unrealized gains     Gross unrealized losses     Fair value  
Corporate bond     18,521       57       (29 )   $ 18,549  
Agency bond     40,487       63       (64 )   $ 40,486  
US Government     8,538       13       (34 )   $ 8,517  
Total     67,546       133       (127 )     67,552  

 

As of June 30, 2024 and December 31, 2023, no continuous unrealized losses for twelve months or greater were identified.

 

The allowance for credit losses for the six months ended June 30, 2024 was not material.

 

The following table summarizes the Company’s marketable securities by contractual maturities:

 

    June 30,
2024
 
    (Unaudited)  
Due in 1 year or less   $ 71,630  
Due in 1 year through 2 years     60,652  
Total   $ 132,282  

 

F-12


 

  Cellebrite DI Ltd. and its Subsidiaries
   
Notes to Interim Consolidated Financial Statements
U.S. dollars (in thousands, except share and per share data)

 

Note 4. Derivative Instruments

 

Company’s risk management strategy includes the use of derivative financial instruments to reduce the volatility of earnings and cash flows associated with changes in foreign currency exchange rates.

 

ASC 815, "Derivatives and Hedging" ("ASC 815"), requires the Company to recognize all of its derivative instruments as either assets or liabilities on the balance sheet at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship. For those derivative instruments that are designated and qualify as hedging instruments, an entity must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge or a hedge of a net investment in a foreign operation.

 

Gains and losses on derivatives instruments that are designated and qualify as a cash flow hedge (i.e., hedging the exposure to variability in expected future cash flows that are attributable to a particular risk), are recorded in accumulated other comprehensive income (loss) and reclassified into statement of income in the same accounting period in which the designated forecasted transaction or hedged item affects earnings.

 

The Company entered into option and forward contracts to hedge a portion of anticipated New Israeli Shekel ("NIS") payroll and benefit payments. These derivative instruments are designated as cash flow hedges, as defined by ASC 815 and accordingly are measured at fair value. These transactions are effective and, as a result, gain or loss on the derivative instruments are reported as a component of accumulated other comprehensive income and reclassified as Cost of revenues and Operating expenses, at the time that the hedged income/expense is recorded.

 

    Net Notional amount     Fair value  
    June 30,
2024
    December 31,
2023
    June 30,
2024
    December 31,
2023
 
    (Unaudited)           (Unaudited)        
Option contracts to hedge payroll                        
expenses NIS     26,370       32,158       29       995  

 

The Company currently hedges its exposure to the variability in future cash flows for a maximum period of one year. As of June 30, 2024, the Company expects to reclassify all of its unrealized gains and losses from accumulated other comprehensive loss to earnings during the next twelve months. The fair value of the Company's outstanding derivative instruments on June 30, 2024 and December 31, 2023 is summarized below:

 

        Fair value of derivative instruments  
        June 30,     December 31,  
        2024     2023  
    Balance Sheet line item   (Unaudited)        
Derivative liabilities:                    
Foreign exchange option contracts   Prepaid expenses and other current assets   $ 291     $ 1,159  
Foreign exchange option contracts   Other account payable   $ (262 )   $ (164 )

 

F-13


 

  Cellebrite DI Ltd. and its Subsidiaries
   
Notes to Interim Consolidated Financial Statements
U.S. dollars (in thousands, except share and per share data)

 

The effect of derivative instruments in cash flow hedging relationship on other comprehensive loss for the six month ended June 30, 2024 and 2023, is summarized below:

 

    Amount of loss recognized in other comprehensive loss on derivative, net of tax  
    Six months ended June 30,  
    2024     2023  
    (Unaudited)     (Unaudited)  
Derivatives in foreign exchange cash flow hedging relationships:            
Forward contracts    
      (151 )
Option contracts     (652 )     (520 )
    $ (652 )   $ (671 )

 

Derivatives in foreign exchange cash flow hedging relationships for the six month ended June 30, 2024 and 2023, is summarized below:

 

        Amount of gain reclassified from other comprehensive income into (expenses) income, net of tax  
        Six months ended June 30,  
        2024     2023  
    Statements of income line   (Unaudited)     (Unaudited)  
Option contracts to hedge payroll and facility expenses   Cost of revenues and operating expenses       (198 )         405  
Forward contracts to hedge payroll and facility expenses   Cost of revenues, operating expenses and financial expenses           292  
        $ (198 )   $ 697  

 

F-14


 

  Cellebrite DI Ltd. and its Subsidiaries
   
Notes to Interim Consolidated Financial Statements
U.S. dollars (in thousands, except share and per share data)

 

Note 5. Leases

 

The Company entered into operating leases primarily for offices. The leases have remaining lease terms of up to 7.7 years, some of which may include options to extend the leases for up to an additional of 1 year.

 

The components of operating lease costs were as follows:

 

    Six months ended June 30,  
    2024     2023  
    (Unaudited)     (Unaudited)  
Operating lease cost   $ 2,782     $ 2,485  
Short-term lease cost     93       135  
Variable lease cost     166       76  
Total net lease costs   $ 3,041     $ 2,696  

 

Supplemental balance sheet information related to operating leases is as follows:

 

    June 30,     December 31,  
    2024     2023  
    (Unaudited)        
Operating lease ROU assets   $ 11,708     $ 14,260  
Operating lease liabilities, current   $ 4,521     $ 4,972  
Operating lease liabilities, long-term   $ 7,155     $ 9,157  
Weighted average remaining lease term (in years)     4.63       4.59  
Weighted average discount rate     2.73 %     2.48 %

 

Minimum lease payments for the Company’s ROU assets over the remaining lease periods as of June 30, 2024, are as follows:

 

    Operating Leases  
2024   $ 3,012  
2025     4,687  
2026     2,279  
2027     1,196  
2028 and thereafter     3,417  
         
Total undiscounted lease payments     14,591  
Less: imputed interest     (2,915 )
         
Present value of lease liabilities   $ 11,676  

 

Note 6. Commitments and contingent liabilities

 

From time to time, the Company may be involved in various claims and legal proceedings. The Company reviews the status of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated the Company would accrue a liability for the estimated loss. As of June 30, 2024 and December 31, 2023, the Company is not involved in any claims or legal proceedings which require accrual of liability for the estimated loss.

 

 

F-15


 

  Cellebrite DI Ltd. and its Subsidiaries
   
Notes to Interim Consolidated Financial Statements
U.S. dollars (in thousands, except share and per share data)

 

Note 7. Shareholders’ equity

 

a. Ordinary Shares

 

As of June 30, 2024 and December 31, 2023, the Company was authorized to issue 3,454,112,863 shares of par value NIS 0.00001 per share Ordinary Share. The voting, dividend and liquidation rights of the holders of the Company’s common share is subject to and qualified by the rights, powers and preferences of the holders of the preferred shares as set forth below.

 

Ordinary Shares confers upon its holders the following rights:

 

i. The right to participate and vote in the Company’s general meetings. Each share will entitle its holder, when attending and participating in the voting to one vote;

 

ii. Dividends or distribution shall be paid or be made to the holders of Ordinary Shares, shall be in an amount equal the product of the dividend or distribution payable or made on each Ordinary Share determined as if all preferred shares had been converted into Ordinary Shares and the number of Ordinary Shares issuable upon conversion of such preferred share, in each case calculated on the record date for determination of holders entitled to receive such dividend or distribution; and

 

iii. The right to a share in the distribution of the Company’s excess assets upon liquidation pro rata to the par value of the share held by them.

 

b. Option Plan and RSUs:

 

A summary of the status of options under the Plan as of June 30, 2024 and changes during the relevant period ended on that date is presented below:

 

    Number of
options
    Weighted-
average
exercise price
    Weighted-
average
remaining
contractual
term (in years)
    Aggregate
intrinsic value
 
    (Unaudited)  
Outstanding at December 31, 2023     15,728,176     $ 3.83       6.23       75,997  
Granted     769,008       10.41                  
Exercised     2,487,028       2.80                  
Forfeited     122,823       5.95                  
Expired     5,297       8.27                  
Outstanding at June 30, 2024     13,882,036     $ 4.36       6.15       105,409  
Exercisable at June 30, 2024     9,905,245     $ 3.21       5.06       86,556  

 

The weighted average fair values at grant date of options granted for the six months ended June 30, 2024 and 2023 were $5.50 and $2.65 per share, respectively.

 

A summary of the status of RSUs under the Plan as of June 30, 2024 and changes during the relevant period ended on that date is presented below:

 

    June 30,
2024
 
    (Unaudited)  
Unvested at beginning of year     8,160,149  
Granted     2,547,701  
Vested     1,708,047  
Forfeited     518,079  
Unvested at end of the period     8,481,724  

 

The weighted average fair value at grant date of RSUs granted for the six months ended June 30, 2024 was $9.64.

 

F-16


 

  Cellebrite DI Ltd. and its Subsidiaries
   
Notes to Interim Consolidated Financial Statements
U.S. dollars (in thousands, except share and per share data)

 

The Company used the following weighted-average assumptions for options granted to employees and non-employees:

 

    Six months ended
June 30,
 
    2024  
Contractual period in years     10  
Volatility     45.9% - 50.1%  
Risk free interest rate     4.2% - 4.4%  
Dividend yield     0%
Exercise price     $9.25 - $11.53  
Fair value of Ordinary Share     $9.25 - $11.53  
Expected term     6.12  

 

c. 2021 Employee Share Purchase Plan:

 

On August 5, 2021, the Company adopted the 2021 Employee Share Purchase Plan (“ESPP”).

 

The aggregate number of Shares that may be issued pursuant to rights granted under the ESPP shall be 1,871,687 Shares. In addition, on the first day of each calendar year beginning on January 1, 2023 and ending on and including January 1, 2033, the number of Shares available for issuance under the Plan shall be increased by that number of Shares equal to the lesser of (a) 1.0% of the Shares outstanding on the last day of the immediately preceding calendar year, as determined on a fully diluted basis, and (b) such smaller number of Shares as may be determined by the Board. If any right granted under the ESPP shall for any reason terminate without having been exercised, the Shares not purchased under such right shall again become available for issuance under the ESPP.

 

The total equity-based compensation expense related to all of the Company's equity-based awards recognized for the six months ended June 30, 2024 and 2023, was comprised as follows:

 

    Six months ended June 30,  
    2024     2023  
    (Unaudited)     (Unaudited)  
Cost of revenues   $ 1,093     $ 800  
Research and development     3,071       2,281  
Sales and marketing     4,391       3,179  
General and administrative     3,696       2,797  
      12,251       9,057  

 

As of June 30, 2024, there were unrecognized compensation costs of $64,726, which are expected to be recognized over a weighted average period of approximately 2.98 years.

 

Note 8. Net loss per share

 

The following table sets forth the computation of basic losses per share:

 

    Six months ended June 30,  
    2024     2023  
    (Unaudited)     (Unaudited)  
Numerator:            
Net loss   $ (95,183 )   $ (72,953 )
Basic net loss attributable to Ordinary shareholders     (95,183 )     (72,953 )
Basic net loss attributable to Restricted sponsor shares    
     
 
                 
Denominator:                
Weighted average number of Ordinary Shares used in computing basic loss per share     197,840,662       187,239,136  
Basic net loss per share of Ordinary shareholders   $ (0.48 )   $ (0.37 )
Weighted average number of Ordinary Shares used in computing diluted net loss per share     197,840,662       187,239,136  
Diluted loss per share of Ordinary shareholders   $ (0.48 )   $ (0.37 )

 

The number of shares related to outstanding anti-dilutive options excluded from the calculations of diluted net earnings per share was 12,776,024 for the six months ended June 30, 2024.

 

F-17


 

  Cellebrite DI Ltd. and its Subsidiaries
   
Notes to Interim Consolidated Financial Statements
U.S. dollars (in thousands, except share and per share data)

 

Note 9. Fair value measurements

 

The following table presents information about the Company’s assets and liabilities fair value at June 30, 2024 and December 31, 2023 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:

 

    As of June 30, 2024  
    Fair value measurements using input type  
    Level 1     Level 2     Level 3     Total  
Assets:                        
Cash equivalents:                        
Money market funds   $ 59,214     $
    $
    $ 59,214  
Commercial deposits    
      756      
      756  
Marketable securities:    
 
     
 
     
 
     
 
 
Corporate and Agency bonds    
      106,994      
      106,994  
Treasury bills             10,028               10,028  
US Government    
      15,260      
      15,260  
Foreign currency derivative contracts    
      291      
      291  
                                 
Total financial assets   $ 59,214     $ 133,329     $
    $ 192,543  
                                 
Liabilities:                                
Restricted Sponsor Shares   $
    $
    $ (75,230 )   $ (75,230 )
Price Adjustment Shares    
     
      (134,758 )     (134,758 )
Public Warrants     (57,798 )    
     
      (57,798 )
Private Placement Warrants    
     
      (35,712 )     (35,712 )
Foreign currency derivative contracts    
      (262 )    
      (262 )
                                 
Total financial liabilities   $ (57,798 )   $ (262 )   $ (245,700 )   $ (303,760 )

 

    As of December 31, 2023  
    Fair value measurements using input type  
    Level 1     Level 2     Level 3     Total  
Assets:                        
Cash equivalents:                        
Money market funds   $ 120,969     $
    $
    $ 120,969  
Commercial deposits    
      3,260      
      3,260  
Marketable securities:    
 
     
 
     
 
     
 
 
Corporate and Agency bonds    
      59,035      
      59,035  
US Government    
      8,517      
      8,517  
Foreign currency derivative contracts    
      1,159      
      1,159  
                                 
Total financial assets   $ 120,969     $ 71,971     $
    $ 192,940  
                                 
Liabilities:                                
Restricted Sponsor Shares   $
    $
    $ (47,247 )   $ (47,247 )
Price Adjustment Shares    
     
      (81,715 )     (81,715 )
Public Warrants     (31,399 )    
     
      (31,399 )
Private Placement Warrants    
     
      (22,718 )     (22,718 )
Foreign currency derivative contracts    
      (164 )    
      (164 )
                                 
Total financial liabilities   $ (31,399 )   $ (164 )   $ (151,680 )   $ (183,243 )

 

Warrant liability

 

The Company has classified the warrants assumed during the Merger (both public and private) as a liability pursuant to ASC 815-40 since the warrants do not meet the equity classification conditions. Accordingly, the Company measured the warrants at their fair value. The warrants liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in our statement of comprehensive loss.

 

F-18


 

  Cellebrite DI Ltd. and its Subsidiaries
   
Notes to Interim Consolidated Financial Statements
U.S. dollars (in thousands, except share and per share data)

 

    Public Warrants     Private Placement
Warrants
    Total Warrant
liability
 
    (Unaudited)  
Balance, December 31, 2023   $ 31,399     $ 22,718     $ 54,117  
Change in fair value of warrant liability     26,399       12,994       39,393  
Balance, June 30, 2024   $ 57,798     $ 35,712     $ 93,510  

 

The estimated fair value of the private placement warrant liabilities is determined using Level 3 inputs. Inherent in a Black-Scholes valuation model are assumptions related to expected share-price volatility, expiration, risk-free interest rate and dividend yield. The Company estimates the volatility of its common share based on historical volatility of select peer companies that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expiration of the warrants. The dividend yield is based on the historical rate, which the Company anticipates will remain at 0%.

 

The following table provides quantitative information regarding Level 3 fair value measurements inputs as their measurement dates:

 

    As of
June 30,
2024
    As of December 31,
2023
 
    (Unaudited)        
Number of private placement warrants     9,666,667       9,666,667  
Exercise price   $ 11.5     $ 11.5  
Share price   $ 11.95     $ 8.66  
Expiration term (in years)     2.16       2.66  
Volatility     44.2 %     51.9 %
Risk-free Rate     4.72 %     4.10 %
Dividend yield     0 %     0 %

 

Restricted sponsor shares liability and Price adjustment shares liability

 

The restricted Sponsor shares liability and Price adjustment shares are measured at fair value using Level 3 inputs.

 

The Company has determined that the price adjustment shares, and the restricted sponsor shares should be accounted for as liabilities measured at fair value through earnings since the restricted sponsor shares and the price adjustment shares are not eligible to be classified as equity pursuant to ASC 815-40

 

    Restricted sponsor
shares
    Price adjustment
shares
    Total  
    (Unaudited)  
Balance, December 31, 2023   $ 47,247     $ 81,715     $ 128,962  
Change in fair value of warrant liability     27,983       53,043       81,026  
Balance, June 30,2024   $ 75,230     $ 134,758     $ 209,988  

 

The following table provides quantitative information regarding Level 3 fair value measurements inputs as their measurement dates:

 

    June 30, 2024     December 31, 2023  
    Restricted
sponsor
shares
    Price
adjustment
shares
    Restricted
sponsor
shares
    Price
adjustment
shares
 
    (Unaudited)        
Number of shares     7,500,000       15,000,000       7,500,000       15,000,000  
Share price     $12.5-$30       $12.5-$17.5       $12.5-$30       $12.5-$17.5  
Remaining exercise period     4.16       2.16       4.66       2.66  
Share value     $6.32-$11.27       $7.28-$10.61       $3.62-$7.17       $4.47-$6.31  

 

F-19


 

  Cellebrite DI Ltd. and its Subsidiaries
   
Notes to Interim Consolidated Financial Statements
U.S. dollars (in thousands, except share and per share data)

 

Note 10. Revenues

 

Disaggregation of Revenues

 

The following table provides information about disaggregated revenue by geographical areas

 

    Six months ended June 30,  
    2024     2023  
    (Unaudited)     (Unaudited)  
EMEA   $ 65,096     $ 52,141  
America     97,368       77,223  
APAC     22,832       18,554  
Total   $ 185,296     $ 147,918  

 

Contract Balances

 

The following table provides information about accounts receivable, contract assets, and contract liabilities from contracts with customers:

 

    June 30,
2024
    December 31,
2023
 
    (Unaudited)        
Contract liabilities, current   $ 183,938     $ 195,725  
Contract liabilities, non-current     42,369     $ 47,098  

 

Contract assets consist of unbilled accounts receivable, which occur when a right to consideration for the Company’s performance under the customer contract occurs before invoicing to the customer. The increase in contract balances is consistent with the increase in the overall operation of the Company.

 

Contract liabilities consist of deferred revenue. Revenue is deferred when the Company invoices in advance of performance under a contract. The current portion of the deferred revenue balance is recognized as revenue during the 12-month period after the balance sheet date. The non current portion of the deferred revenue balance is recognized as revenue following the 12-month period after the balance sheet date. Of the $242,823 and $194,882 of deferred revenue as of December 31, 2023 and 2022, respectively, the Company recognized $122,089 and $97,044 as revenue during the six months ended June 30, 2024 and 2023.

 

Remaining Performance Obligations

 

The Company’s remaining performance obligations are comprised of product and services revenue not yet delivered. As of June 30, 2024 and December 31, 2023, the aggregate amount of the transaction price allocated to remaining performance obligations was $324,110 and $331,996 respectively, which consists of both billed consideration in the amount of $226,307 and $242,823 respectively, and unbilled consideration in the amount of $97,803 and $89,173 respectively, that the Company expects to recognize as revenue. As of June 30, 2024, the Company expects to recognize the majority of its remaining performance obligations as revenue in the next 12 months.

 

F-20


 

  Cellebrite DI Ltd. and its Subsidiaries
   
Notes to Interim Consolidated Financial Statements
U.S. dollars (in thousands, except share and per share data)

 

Note 11. Financial expenses, net

 

    Six months ended June 30,  
    2024     2023  
    (Unaudited)     (Unaudited)  
Financial income:            
Interest on deposits     5,470       3,187  
Foreign currency translation differences     245       755  
Marketable securities     2,879       699  
Other     7       355  
                 
Total Financial income     8,601       4,996  
                 
Financial expenses:                
Remeasurement of liability instruments     (120,419 )     (78,953 )
Bank charges     (72 )     (158 )
Changes in exchange rates     (1,167 )     (631 )
Other     (21 )     (80 )
                 
Total Financial expenses     (121,679 )     (79,822 )
                 
      (113,078 )     (74,826 )

 

Note 12. Transactions and Balances with Related Parties

 

SUN Corporation, the Company’s primary shareholder is also a reseller of the Company in the Japanese market.

 

a. Transactions with SUN Corporation

 

    Six months ended June 30,  
    2024     2023  
    (Unaudited)     (Unaudited)  
Revenues     2,454       1,957  

 

b. Balances with SUN Corporation

 

    June 30,
2024
    December 31,
2023
 
    (Unaudited)        
Trade Receivables     125       345  

 

Note 13. Subsequent events

 

On July 17, 2024, the Company completed the acquisition of 100% of the shares of Cyber Technology Services, Inc. (“CyTech”), a US cybersecurity expertise, digital forensics and incident response services company, for the total base consideration of $3.75 million. The acquisition would be accounted for as a business combination.

 

On August 14, 2024, the Company achieved the first trigger event (as defined in the Business Combination Agreement) regarding the price adjustment shares and the restricted sponsor shares by reaching a share price of $12.5 for twenty consecutive trading days’. The company is required to issue outstanding ordinary shares for its Shareholders and release restrictions for its Sponsors of 5,000,000 and 3,000,000, respectively. (See Note 9 for additional information).

 

F-21

 

false --12-31 Q2 0001854587 0001854587 2024-01-01 2024-06-30 0001854587 2024-06-30 0001854587 2023-12-31 0001854587 clbt:SubscriptionMember us-gaap:SubscriptionAndCirculationMember 2024-01-01 2024-06-30 0001854587 clbt:SubscriptionMember us-gaap:SubscriptionAndCirculationMember 2023-01-01 2023-06-30 0001854587 clbt:SubscriptionMember us-gaap:LicenseMember 2024-01-01 2024-06-30 0001854587 clbt:SubscriptionMember us-gaap:LicenseMember 2023-01-01 2023-06-30 0001854587 clbt:SubscriptionMember 2024-01-01 2024-06-30 0001854587 clbt:SubscriptionMember 2023-01-01 2023-06-30 0001854587 clbt:OtherNonRecurringMember 2024-01-01 2024-06-30 0001854587 clbt:OtherNonRecurringMember 2023-01-01 2023-06-30 0001854587 clbt:ProfessionalServicesMember 2024-01-01 2024-06-30 0001854587 clbt:ProfessionalServicesMember 2023-01-01 2023-06-30 0001854587 2023-01-01 2023-06-30 0001854587 us-gaap:CommonStockMember 2023-12-31 0001854587 clbt:ShareCapitalMember 2023-12-31 0001854587 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001854587 clbt:TreasuryShareMember 2023-12-31 0001854587 us-gaap:RetainedEarningsMember 2023-12-31 0001854587 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001854587 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001854587 clbt:ShareCapitalMember 2024-01-01 2024-06-30 0001854587 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001854587 clbt:TreasuryShareMember 2024-01-01 2024-06-30 0001854587 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0001854587 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-06-30 0001854587 us-gaap:CommonStockMember 2024-06-30 0001854587 clbt:ShareCapitalMember 2024-06-30 0001854587 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001854587 clbt:TreasuryShareMember 2024-06-30 0001854587 us-gaap:RetainedEarningsMember 2024-06-30 0001854587 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001854587 us-gaap:CommonStockMember 2022-12-31 0001854587 clbt:ShareCapitalMember 2022-12-31 0001854587 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001854587 clbt:TreasuryShareMember 2022-12-31 0001854587 us-gaap:RetainedEarningsMember 2022-12-31 0001854587 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001854587 2022-12-31 0001854587 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001854587 clbt:ShareCapitalMember 2023-01-01 2023-06-30 0001854587 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001854587 clbt:TreasuryShareMember 2023-01-01 2023-06-30 0001854587 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001854587 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0001854587 us-gaap:CommonStockMember 2023-06-30 0001854587 clbt:ShareCapitalMember 2023-06-30 0001854587 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001854587 clbt:TreasuryShareMember 2023-06-30 0001854587 us-gaap:RetainedEarningsMember 2023-06-30 0001854587 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001854587 2023-06-30 0001854587 clbt:CorporateBondMember 2024-06-30 0001854587 clbt:AgencyBondMember 2024-06-30 0001854587 clbt:TreasuryBillsMember 2024-06-30 0001854587 clbt:USGovernmentMember 2024-06-30 0001854587 clbt:CorporateBondMember 2023-12-31 0001854587 clbt:AgencyBondMember 2023-12-31 0001854587 clbt:USGovernmentMember 2023-12-31 0001854587 clbt:NetNotionalAmountMember 2024-01-01 2024-06-30 0001854587 clbt:NetNotionalAmountMember 2023-01-01 2023-12-31 0001854587 clbt:FairValueMember 2024-01-01 2024-06-30 0001854587 clbt:FairValueMember 2023-01-01 2023-12-31 0001854587 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeOptionMember 2024-06-30 0001854587 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeOptionMember 2023-12-31 0001854587 clbt:OtherAccountPayableMember us-gaap:ForeignExchangeOptionMember 2024-06-30 0001854587 clbt:OtherAccountPayableMember us-gaap:ForeignExchangeOptionMember 2023-12-31 0001854587 us-gaap:ForwardContractsMember 2024-01-01 2024-06-30 0001854587 us-gaap:ForwardContractsMember 2023-01-01 2023-06-30 0001854587 clbt:OptionContractsMember 2024-01-01 2024-06-30 0001854587 clbt:OptionContractsMember 2023-01-01 2023-06-30 0001854587 clbt:OptionContractsMember us-gaap:OperatingExpenseMember 2024-01-01 2024-06-30 0001854587 clbt:OptionContractsMember us-gaap:OperatingExpenseMember 2023-01-01 2023-06-30 0001854587 us-gaap:ForwardContractsMember clbt:FinancialExpensesMember 2023-01-01 2023-06-30 0001854587 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001854587 2023-12-30 0001854587 2023-12-31 2023-12-31 0001854587 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001854587 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001854587 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001854587 srt:MinimumMember 2024-01-01 2024-06-30 0001854587 srt:MaximumMember 2024-01-01 2024-06-30 0001854587 srt:MinimumMember 2024-06-30 0001854587 srt:MaximumMember 2024-06-30 0001854587 us-gaap:CostOfSalesMember 2024-01-01 2024-06-30 0001854587 us-gaap:CostOfSalesMember 2023-01-01 2023-06-30 0001854587 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001854587 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001854587 us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-06-30 0001854587 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-06-30 0001854587 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0001854587 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001854587 us-gaap:FairValueInputsLevel1Member 2024-06-30 0001854587 us-gaap:FairValueInputsLevel2Member 2024-06-30 0001854587 us-gaap:FairValueInputsLevel3Member 2024-06-30 0001854587 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001854587 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001854587 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001854587 clbt:PublicWarrantsMember 2023-12-31 0001854587 us-gaap:PrivatePlacementMember 2023-12-31 0001854587 clbt:WarrantLiabilityMember 2023-12-31 0001854587 clbt:PublicWarrantsMember 2024-01-01 2024-06-30 0001854587 us-gaap:PrivatePlacementMember 2024-01-01 2024-06-30 0001854587 clbt:WarrantLiabilityMember 2024-01-01 2024-06-30 0001854587 clbt:PublicWarrantsMember 2024-06-30 0001854587 us-gaap:PrivatePlacementMember 2024-06-30 0001854587 clbt:WarrantLiabilityMember 2024-06-30 0001854587 us-gaap:MeasurementInputExercisePriceMember 2024-06-30 0001854587 us-gaap:MeasurementInputExercisePriceMember 2023-12-31 0001854587 us-gaap:MeasurementInputSharePriceMember 2024-06-30 0001854587 us-gaap:MeasurementInputSharePriceMember 2023-12-31 0001854587 us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001854587 us-gaap:MeasurementInputExpectedTermMember 2023-12-31 0001854587 us-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001854587 us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001854587 us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001854587 us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001854587 us-gaap:MeasurementInputExpectedDividendRateMember 2024-06-30 0001854587 us-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0001854587 clbt:RestrictedSponsorSharesMember 2023-12-31 0001854587 clbt:PriceAdjustmentSharesMember 2023-12-31 0001854587 clbt:RestrictedSponsorSharesMember 2024-01-01 2024-06-30 0001854587 clbt:PriceAdjustmentSharesMember 2024-01-01 2024-06-30 0001854587 clbt:RestrictedSponsorSharesMember 2024-06-30 0001854587 clbt:PriceAdjustmentSharesMember 2024-06-30 0001854587 clbt:PriceAdjustmentMember 2024-06-30 0001854587 clbt:PriceAdjustmentMember 2023-12-31 0001854587 srt:MinimumMember clbt:RestrictedSponsorSharesMember 2024-06-30 0001854587 srt:MaximumMember clbt:RestrictedSponsorSharesMember 2024-06-30 0001854587 srt:MinimumMember clbt:PriceAdjustmentMember 2024-06-30 0001854587 srt:MaximumMember clbt:PriceAdjustmentMember 2024-06-30 0001854587 srt:MinimumMember clbt:RestrictedSponsorSharesMember 2023-12-31 0001854587 srt:MaximumMember clbt:RestrictedSponsorSharesMember 2023-12-31 0001854587 srt:MinimumMember clbt:PriceAdjustmentMember 2023-12-31 0001854587 srt:MaximumMember clbt:PriceAdjustmentMember 2023-12-31 0001854587 2023-01-01 2023-12-31 0001854587 us-gaap:EMEAMember 2024-01-01 2024-06-30 0001854587 us-gaap:EMEAMember 2023-01-01 2023-06-30 0001854587 srt:AmericasMember 2024-01-01 2024-06-30 0001854587 srt:AmericasMember 2023-01-01 2023-06-30 0001854587 srt:AsiaPacificMember 2024-01-01 2024-06-30 0001854587 srt:AsiaPacificMember 2023-01-01 2023-06-30 0001854587 clbt:CyberTechnologyServicesIncMember us-gaap:SubsequentEventMember 2024-07-17 0001854587 clbt:CyberTechnologyServicesIncMember us-gaap:SubsequentEventMember 2024-07-17 2024-07-17 0001854587 clbt:CyberTechnologyServicesIncMember us-gaap:SubsequentEventMember 2024-08-14 0001854587 us-gaap:SubsequentEventMember 2024-08-14 2024-08-14 iso4217:USD iso4217:ILS xbrli:shares xbrli:shares iso4217:USD xbrli:shares xbrli:pure
EX-99.2 3 ea021071001ex99-2_cellebrite.htm OPERATING AND FINANCIAL REVIEW AND PROSPECTS FOR THE SIX MONTHS ENDED JUNE 30, 2024

Exhibit 99.2

 

  Cellebrite DI Ltd. and its Subsidiaries
   
Notes to Interim Consolidated Financial Statements
U.S. dollars (in thousands, except share and per share data)

 

OPERATING AND FINANCIAL REVIEW AND PROSPECTS

 

This operating and financial review and prospects provides information that we believe to be relevant to an assessment and understanding of our results of operations and financial condition for the period described. This discussion should be read in conjunction with our consolidated interim financial statements and the notes to the financial statements for the six months ended June 30, 2024, furnished with our Report of Foreign Private Issuer on Form 6-K. In addition, this information should also be read in conjunction with the information contained in our Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC on March 21, 2024 and as amended on April 12, 2024, including the consolidated annual financial statements as of December 31, 2023 and their accompanying notes included therein and “Item 5. Operating and Financial Review and Prospects.”

 

Forward-Looking Statements

 

This operating and financial review and prospects includes “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “will,” “appear,” “approximate,” “foresee,” “might,” “possible,” “potential,” “believe,” “could,” “predict,” “should,” “could,” “continue,” “expect,” “estimate,” “may,” “plan,” “outlook,” “future” and “project” and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward looking statements include estimated financial information. Such forward-looking statements including statements related to the performance, strategies, prospects, and other aspects of Cellebrite’s business are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward looking statements. These factors include, but are not limited to: Cellebrite’s ability to keep pace with technological advances and evolving industry standards; Cellebrite’s material dependence on the purchase, acceptance and use of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite’s solutions; Cellebrite’s failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; intense competition in all of Cellebrite’s markets; the inadvertent or deliberate misuse of Cellebrite’s solutions; failure to manage its growth effectively; Cellebrite’s ability to introduce new solutions and add-ons; its dependency on its customers renewing their subscriptions; the low volume of business Cellebrite conducts via e-commerce; risks associated with the use of artificial intelligence; the risk of requiring additional capital to support the growth of its business; risks associated with higher costs or unavailability of materials used to create its hardware product components; fluctuations in foreign currency exchange rates; lengthy sales cycle for some of Cellebrite’s solutions; near term declines in new or renewed agreements; risks associated with inability to retain qualified personnel and senior management; the security of Cellebrite’s operations and the integrity of its software solutions; risks associated with the negative publicity related to Cellebrite’s business and use of its products; risks related to Cellebrite’s intellectual property; the regulatory constraints to which Cellebrite is subject; risks associated with Cellebrite’s operations in Israel, including the ongoing Israel-Hamas war and the risk of a greater regional conflict; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite’s shares; changing tax laws and regulations; risks associated with joint ventures, partnerships and strategic initiatives; risks associated with Cellebrite’s significant international operations; risks associated with Cellebrite’s failure to comply with anti-corruption, trade compliance, anti-money-laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite’s existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite’s current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled “Risk Factors” in Cellebrite’s annual report on Form 20-F filed with the SEC on March 21, 2024 and as amended on April 12, 2024, and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission (“SEC”), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

 

Unless otherwise indicated or the context otherwise requires, all references to “Cellebrite,” the “Company,” “we,” “our,” “us,” or similar terms refer to Cellebrite DI Ltd and its subsidiaries. 

 

 


 

  Cellebrite DI Ltd. and its Subsidiaries
   
Notes to Interim Consolidated Financial Statements
U.S. dollars (in thousands, except share and per share data)

 

Key Components of Results of Operations

 

Revenue

 

Revenue consists of subscription, other non-recurring, and professional services.

 

Subscription. Subscription revenue is comprised of subscription services and term-license revenue. The subscription services revenue is the revenue that is recognized over the life of the subscription and the term-license revenue is what is immediately recognized upon the sale of an on-premise license. In connection with our term-based license and perpetual license arrangements, we generate revenue through maintenance and support under renewable subscription, fee-based contracts that include unspecified software updates and upgrades released when and if available as well as software patches and support. Customers with active subscriptions are also entitled to our technical customers’ support.
     
Other non-recurring. Other non-recurring revenue reflects the revenue recognized from sales of other non-recurring related to offerings such as hardware sold mainly in conjunction with new software license, perpetual license and usage-based fees. Other non-recurring fees are recognized upfront assuming all revenue recognition criteria are satisfied.
     
Professional Services. Professional Services consists of revenue related to: (i) certified training sessions by Cellebrite Training; (ii) our advanced services; (iii) implementation of our products in connection with our software licenses and (iv) on premise contracted customer success and technical support. The revenue of professional services is recognized upon the delivery of our services.

 

Cost of Revenue

 

Cost of revenue consists of cost of subscription, other non-recurring, and cost of professional services.

 

Cost of Subscription. Cost of subscription revenue includes all direct cost to deliver and support subscription services, including salaries and related employees’ expenses, allocated overhead such as facilities expenses, third party license fees, fees paid to OEMs, hosting, and IT related expenses . We recognize these costs and expenses upon occurrence.
     
  Cost of Other non- recurring. Cost of other non-recurring revenue includes all direct costs to deliver other non-recurring revenue, including HW costs, fees paid for third party products, materials, salaries and related employees’ expenses, allocated overhead such as depreciation of equipment and IT related expenses, warehouse, manufacturing and supply chain costs. We recognize these costs and expenses upon occurrence.
     
Cost of Professional Service. Cost of professional service revenue includes salaries and related employees’ expenses, subcontractors and all direct costs related to services such as services materials, allocated overhead for depreciation of equipment, facilities and IT related costs. We recognize these costs and expenses upon occurrence.

 

Gross Profit and Gross Margin

 

Gross profit is revenue less cost of revenue, and gross margin is gross profit as a percentage of revenue. Gross profit has been and will continue to be affected by various factors, including our revenue mix, the selling price to our customers, the cost of our manufacturing facility, supply chain, hosting, salaries, other related costs to our employees and subcontractors and overhead. We expect that our gross margin will fluctuate from period to period depending on the interplay of these various factors.

 

2


 

  Cellebrite DI Ltd. and its Subsidiaries
   
Notes to Interim Consolidated Financial Statements
U.S. dollars (in thousands, except share and per share data)

 

Operating Expenses

 

Operating expenses consists of research and development, sales and marketing and general and administrative. The most significant components of our operating expenses are personnel costs, which is included in each component of operating expenses and consists of salaries, benefits, bonuses, stock-based compensation and, with regards to sales and marketing expenses, sales commissions.

 

Research and development. Research and development expenses primarily consist of the cost of salaries and related costs for employees, subcontractors cost and depreciation of equipment. Our costs of research and development also include facility-related expenses, recruitment and training, information system licenses, hosting, support and others that contribute to the research and development operations. We focus our research and development efforts on developing new solutions, core technologies and to further enhance the functionality, reliability, performance and flexibility of existing solutions. We believe that our software development teams and our core technologies represent a significant competitive advantage for us and we expect that our research and development expenses will continue to increase, as we invest in research and development headcount to further strengthen and enhance our solutions.

 

Sales and marketing. Sales and marketing expenses primarily consist of personnel, marketing, sales and business development personnel, travel expenses, and commissions earned by our sales personnel. Our costs of sales and marketing also include facility-related expenses, recruitment and training, information system licenses, hosting, support and others that contribute to the sales and marketing operations. We expect that sales and marketing expenses will continue to increase as we continue to invest in our Go-to-Market activities.
     
General and administrative. General and administrative expenses primarily consist of personnel, insurance, consultants and facility-related costs for our executive, finance, legal, IT, human resources, administrative personnel, and other corporate expenses. We anticipate moderate growth in our expenses due to growing our operations. All of the departments are allocated with general and administrative expenses such as rent and related expenses, recruitment and training, information systems licenses, hosting, support and others.

 

Financial Expense, Net

 

Financial expense, net consists primarily of revaluation of derivative warrant liability, restricted sponsor shares and price adjustment shares, interest income on our short-term deposits, fees to banks and foreign currency realized and unrealized income and loss related to the impact of transactions denominated in a foreign currency and financial investment activities.

 

Tax Expense

 

Tax expense (as well as deferred tax assets and liabilities, and liabilities for unrecognized tax benefits) reflects management’s best assessment of estimated current and future taxes to be paid. We are subject to income taxes in Israel, the United States, and numerous other foreign jurisdictions.

 

Significant judgments and estimates are required in determining the consolidated income tax expense.

 

Our income tax rate varies from Israel’s statutory income tax rates, mainly due to differing tax rates and regulations in foreign jurisdictions and other differences between expenses and expenses recognized by other tax authorities in relevant jurisdictions. We expect this fluctuation in income tax rates, as well as its potential impact on our results of operations, to continue.

 

3


 

  Cellebrite DI Ltd. and its Subsidiaries
   
Notes to Interim Consolidated Financial Statements
U.S. dollars (in thousands, except share and per share data)

 

Results of Operations

 

The following table presents interim consolidated statement of operations data for the periods indicated and as a percentage of total revenues (in thousands of U.S. dollars).

 

    Six months ended June 30,  
    2024     2023  
    ($ in thousands)  
Revenue:            
Subscription services   $ 127,841     $ 97,879  
Term-license     36,749       30,609  
Total subscription     164,590       128,488  
Other non-recurring     7,054       4,890  
Professional services     13,652       14,540  
Total Revenue   $ 185,296       147,918  
Cost of revenue:                
Cost of subscription services     12,197       9,438  
Cost of term-license           2  
Total subscription     12,197       9,440  
Cost of other non-recurring     7,920       5,907  
Cost of professional services     9,408       10,090  
Total cost of revenue     29,525       25,437  
Gross profit   $ 155,771     $ 122,481  
Operating expenses:                
Research and development     46,890       42,184  
Sales and marketing     64,379       54,346  
General and administrative     22,768       21,192  
Total operating expenses     134,037       117,722  
Operating income   $ 21,734     $ 4,759  
Financial expense, net     (113,078 )     (74,826 )
Loss before tax     (91,344 )     (70,067 )
Tax expense     3,839       2,886  
Net loss   $ (95,183 )   $ (72,953 )

 

Revenue

 

    Six months ended June 30,     Change  
    2024     2023     Amount     Percent  
    ($ in thousands)  
Subscription services   $ 127,841     $ 97,879     $ 29,962       31 %
Term-license     36,749       30,609       6,140       20 %
Total subscription     164,590       128,488       36,102       28 %
Other non-recurring     7,054       4,890       2,164       44 %
Professional services     13,652       14,540       (888 )     (6 )%
Total Revenue   $ 185,296     $ 147,918     $ 37,378       25 %

 

4


 

  Cellebrite DI Ltd. and its Subsidiaries
   
Notes to Interim Consolidated Financial Statements
U.S. dollars (in thousands, except share and per share data)

 

Subscription

 

Subscription revenue is comprised of subscription services and term-license revenue. The subscription services revenue is the revenue that is recognized over the life of the subscription and the term-license revenue is what is immediately recognized upon the sale of an on-premise subscription license. Subscription revenue increased by $36.1 million, or 28.1% for the six months ended June 30, 2024, as compared to the six months ended June 30, 2023, primarily due to an increase related to the continuous adoption of our leading Inseyets Collect & Review offering.

 

Other non-recurring

 

Other non-recurring increased by $2.2 million, or 44.3% for the six months ended June 30, 2024, as compared to the six months ended June 30, 2023,primarily due to the increase in hardware products selling related to our leading Inseyets Collect & Review offering.

 

Professional Services

 

Professional services revenue decreased by $0.9 million, or 6.1% for the six months ended June 30, 2024, as compared to the six months ended June 30, 2023, primarily due to reduced demand for Cellebrite Advanced Services as more customers adopted the advanced lawful access solutions.

 

Cost of Revenue

 

    Six months ended June 30,     Change  
    2024     2023     Amount     Percent  
    ($ in thousands)  
Cost of subscription services   $ 12,197     $ 9,438     $ 2,759       29 %
Cost of term license           2       (2 )     (100 )%
Total subscription     12,197       9,440       2,757       29 %
Cost of other non-recurring     7,920       5,907       2,013       34 %
Cost of professional services     9,408       10,090       (682 )     (7 )%
Cost of Revenue   $ 29,525     $ 25,437     $ 4,088       16 %

 

Cost of Subscription

 

Cost of subscription services increased by $2.8 million, or 29.2% for the six months ended June 30, 2024, as compared to the six months ended June 30, 2023. This increase is primarily due to hosting expenses, and expenses related to customer success, and customer support.

 

Cost of Other non-recurring

 

Cost of other non-recurring revenue increased by $2.0 million, or 34% for the six months ended June 30, 2024, as compared to the six months ended June 30, 2023. This increase is primarily due to higher mix of hardware related revenue and costs associated with upgrading existing hardware.

 

Cost of Professional Services

 

Cost of professional services revenue decreased by $0.7 thousands, or 6.8% for the six months ended June 30, 2024, as compared to the six months ended June 30, 2023. This decrease is primarily due to reduced costs of theadvanced services activity in response to that business decline.

 

5


 

  Cellebrite DI Ltd. and its Subsidiaries
   
Notes to Interim Consolidated Financial Statements
U.S. dollars (in thousands, except share and per share data)

 

Gross Profit and Gross Profit Margin

 

    Six months ended June 30,     Change  
    2024     2023     Amount     Percent  
    ($ in thousands)  
Gross Profit:                        
Subscription services   $ 115,644     $ 88,441     $ 27,203       31 %
Term-license     36,749       30,607       6,142       20 %
Total subscription     152,393       119,048       33,345       28 %
Other non-recurring     (866 )     (1,017 )     151       15 %
Professional services     4,244       4,450       (206 )     (5 )%
Total gross profit   $ 155,771     $ 122,481     $ 33,290       27 %
                                 
Gross Profit Margins:                                
Subscription services     90 %     90 %                
Term-license     100 %     100 %                
Total subscription     93 %     93 %                
Other non-recurring     (12 )%     (21 )%                
Professional services     31 %     31 %                
Total gross margin     84 %     83 %                

 

Subscription

 

Subscription gross profit increased by $33.3 million, or 28%, for the six months ended June 30, 2024, as compared to the six months ended June 30, 2023. Subscription gross profit margin marginally did not change between periods, 93% , for the six months ended June 30, 2024, and for the six months ended June 30, 2023.

 

Other non-recurring

 

Other non-recurring gross profit increased by $0.2 million, or 15%, for the six months ended June 30, 2024, as compared to the six months ended June 30, 2023. Other non-recurring gross lossmargin decreased from (21)% to (12)%, for the six months ended June 30, 2024, as compared to the six months ended June 30, 2023, mainly as a result of reducing hardware costs and improving the pricing of hardware products.

 

Professional Services

 

Professional services gross profit decreased by $0.2 million, or 5% for the six months ended June 30, 2024, as compared to the six months ended June 30, 2023. Services gross profit margin did not change between periods, for the six months ended June 30, 2024, and the six months ended June 30, 2023.

 

Operating Expenses

 

    Six months ended June 30,     Change  
    2024     2023     Amount     Percent  
    ($ in thousands)  
Operating expenses                        
Research and development, net     46,890       42,184       4,706       11 %
Sales and marketing     64,379       54,346       10,033       18 %
General and administrative     22,768       21,192       1,576       7 %
Total operating expenses   $ 134,037     $ 117,722     $ 16,315       14 %

 

6


 

  Cellebrite DI Ltd. and its Subsidiaries
   
Notes to Interim Consolidated Financial Statements
U.S. dollars (in thousands, except share and per share data)

 

Research and development

 

Research and development expenses increased by $4.7 million, or 11%, for the six months ended June 30, 2024, as compared to the six months ended June 30, 2023. This increase is mainly attributable to an increase in salaries and related costs for employees and subcontractors of $3 million, and hosting and IT services of $0.7 million.

 

Sales and marketing

 

Sales and marketing expenses increased by $10.0 million, or 18%, for the six months ended June 30, 2024, as compared to the six months ended June 30, 2023. The increase primarily relates to higher salaries and related costs for employees of $5.3 million and an increase of $2.5 million in marketing activities.

 

General and administrative

 

General and administrative expenses increased by $1.6 million, or 7%, for the six months ended June 30, 2024, as compared to the six months ended June 30, 2023. The increase primarily relates to higher salaries and related costs for employees of $1.3 million and professional service of $2.2 million offset by a decrease relating to insurance expenses.

 

Finance Expense, net

 

Finance expense, net increased by $38.3 million, or 51%, for the six months ended June 30, 2024, as compared to the six months ended June 30, 2023. mainly due to remeasurement to fair value of Restricted Sponsor Shares, Price Adjustment Shares and Derivative warrant liability due to an increase in share price.

 

Taxes Expense

 

Taxes expense increased by $1.0 million, or 33%, for the six months ended June 30, 2024, as compared to the six months ended June 30, 2023, mainly as a result of an improvement in the company's profitability.

 

Liquidity and Capital Resources

 

Our cash, cash equivalents, short-term deposits and marketable securities were $366 million as of June 30, 2024, in comparison to $332 million as of December 31, 2023.

 

We derive our cash primarily from our business operations. Currently, our primary liquidity needs are employee salaries and benefits, product development, and other operating activities to support our organic growth, and our operating cash requirements may increase in the future as we continue to invest in the growth of our company. During the six months ended June 30, 2024 and 2023, our capital expenditures amounted to $4.5 million and $1.9 million, respectively, primarily consisting of expenditures related to property and equipment software and intangible assets, and we expect that our capital expenditures for the next 12 months will relate to the same needs. We may also enter into future arrangements to acquire or invest in businesses, products, services, strategic partnerships, and technologies.

 

We believe that our existing cash and cash equivalents, short-term investments and cash flows from operations will be sufficient to fund our organic operations and capital expenditures for at least the next 12 months. Our future capital requirements will depend on many factors, including our rate of revenue growth, timing of renewals and subscription renewal rates, the expansion of our sales and marketing activities, the timing and extent of spending to support product development efforts and expansion into new customer base, the timing of introductions of new software products and enhancements to existing software products, and the continuing market acceptance of our software offerings and our use of cash to pay for acquisitions. We may be required to seek additional equity or debt financing. In the event that additional financing is required from outside sources, we may not be able to raise it on terms acceptable to us or at all.

 

7


 

  Cellebrite DI Ltd. and its Subsidiaries
   
Notes to Interim Consolidated Financial Statements
U.S. dollars (in thousands, except share and per share data)

 

Credit Facilities

 

We do not have any credit facilities.

 

Cash Flows

 

    Six months ended June 30,  
    2024     2023  
    ($ in thousands)  
Net cash provided by operating activities   $ 24,554     $ 29,052  
Net cash used in investing activities   $ (114,859 )   $ (14,806 )
Net cash provided by financing activities   $ 8,393     $ 8,419  

 

Operating Activities

 

For the six months ended June 30, 2024, cash provided by operating activities was $24.6 million, mainly as a result of an increase in the Company’s non-GAAP operating income

 

For the six months ended June 30, 2023, cash provided by operating activities was $29.1 million, mainly as a result of a decrease in Trade Receivables of $18.1 million and an increase in Deferred Revenue of $10.6 million, as a result of increased sales to customers and collection from customers.

 

Investing Activities

 

Cash used in investing activities for the six months ended June 30, 2024 was $114.9 million, primarily as a result of investment and maturities in short-term deposits, net of $46.5 million, offset by investment and maturities in marketable securities, net of $63.8 million.

 

Cash used in investing activities for the six months ended June 30, 2023 was $14.8 million, primarily as a result of investment and maturities in short-term deposits, net of $15.4 million, offset with investment and maturities in marketable securities, net of $2.5 million.

 

Financing Activities

 

Cash provided by financing activities in the six months ended June 30, 2024 was $8.4 million, mainly as a result of proceeds from exercise of stock options to shares of $6.9 million and proceeds from Employee Share Purchase Plan, net of $1.5 million.

 

Cash provided by financing activities in the six months ended June 30, 2023 was $8.4 million, mainly as a result of proceeds from exercise of stocke options to shares of $7.2 million and proceeds from Employee Share Purchase Plan, net of $1.2 million.

 

 

8